<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18124">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655810</url>
  </required_header>
  <id_info>
    <org_study_id>201102160</org_study_id>
    <nct_id>NCT01655810</nct_id>
  </id_info>
  <brief_title>Vitamin D, Cardiovascular Disease, and African Americans</brief_title>
  <official_title>Vitamin D and Early Markers of Cardiovascular Disease in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      African-Americans have higher rates of cardiovascular disease morbidity and mortality, as
      well as vitamin D deficiency. Multiple observational studies have demonstrated an increased
      risk of vitamin D deficiency in African Americans with type 2 diabetes and correlation
      between cardiovascular disease and vitamin D levels; however, there is a lack of
      interventional trials exploring this connection. The objective of this proposal is to
      address the hypothesis that treatment of vitamin D deficiency in African Americans with type
      2 diabetes will improve subclinical markers of cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a double blinded, randomized controlled trial of vitamin D3
      supplementation, 4,000 international units per day versus 600 international units per day,
      for one year to determine the effects on markers of subclinical cardiovascular disease in
      African Americans with type 2 diabetes and vitamin D deficiency. Outcome assessment will
      focus on changes in carotid intima-medial thickness (CIMT - ultrasound of the thickness of
      blood vessels in the neck), as well as markers of systemic inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in carotid intima-medial thickness</measure>
    <time_frame>0, 6, and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systemic inflammatory markers</measure>
    <time_frame>0, 6, and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>0, 1, 3, 6, 9, and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Calcium</measure>
    <time_frame>0, 1, 3, 6, 9, and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Multivitamin containing cholecalciferol 4000 units orally daily</description>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Multivitamin containing cholecalciferol 600 units orally daily</description>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>500 mg orally twice daily</description>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African Americans of both genders

          -  Age 50-70 years

          -  Type 2 diabetes (A1C &lt; 9.0%), on stable therapy with oral medications, insulin, or a
             combination

          -  25(OH)D level &lt; 20 ng/ml

          -  BP &lt; 140/90 mmHg; LDL &lt; 140 mg/dl

        Exclusion Criteria:

          -  Pregnancy

          -  Cardiovascular disease

          -  Stage 3 or worse chronic kidney disease

          -  High urine or serum calcium or history of recurrent kidney stones

          -  Unstable medical conditions or major systemic diseases such as malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Bernal-Mizrachi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlis Bernal-Mizrachi, MD</last_name>
    <phone>314-362-0934</phone>
    <email>cbernal@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bernal-Mizrachi, MD</last_name>
      <phone>314-362-0934</phone>
      <email>cbernal@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Bernal-Mizrachi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>August 1, 2012</lastchanged_date>
  <firstreceived_date>July 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
